Thursday, May 29th, 2008.

Alfacell Corp. late Wednesday said results from its Phase IIIB clinical trial for Onconase, which was being studied as a potential treatment for unresectable malignant mesothelioma, didn’t meet the trial’s primary endpoint.

The Somerset, N.J.-based biopharmaceutical company said a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen. Alfacell said it will submit a new drug application to the Food and Drug Administration for the treatment of this patient population.

The Phase IIIB trial was designed to show a statistically significant improvement in overall survival for patients treated with a combination of onconase plus doxorubicin versus patients treated with doxorubicin alone.

« Mesothelioma News Main Page.

Posted: Thursday, May 29th, 2008 at 9:54 am; filed under Alfacell, Asbestos & Mesothelioma Studies, Drug Companies, Novel Treatments & Drugs, Onconase (ranpirnase).

You can follow any responses to this entry through the RSS 2.0 feed.

You can skip to the end and leave a response. Pinging is currently not allowed.